# Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

> **NCT01367509** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Methylnaltrexone (MNTX)

## Key facts

- **NCT ID:** NCT01367509
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-01
- **Final completion:** 2005-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01367509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01367509, "Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01367509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*